Business
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by
About this update from Alvotech
[{"type":"text","content":"Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D investments to accelerate pipeline expansion and lower licensing revenues in the period. Phasing of revenues in 2024 resulted in Q2 being the best quarter of the year, while Q4 of is expected to be the best quarter of 2025 Revised full year outlook for total revenues is $570 -$600 million and for Adjusted EBITDA $130 -$150 million, as announced on November 2, 2025. Strong orderbook for product launches in Q4 in ex-US markets will set Alvotech up for continued growth in 2026 In Q3, three new biosimilars were approved in Japan, and were either recommended for approval or received a marketing authorization in Europe Cash balance on September 30, 2025, of $43 million driven by inventory build-up for new launches, CAPEX and bolt-on acquisition. New working capital option of $100 million will be used for working capital needs.Earnings call on Thursday November 13, 2025, 8:00 am ET / 13:00 GMT / 14:00 CET REYKJAVIK, Iceland, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a conference call and live audio webcast on November 13, 2025, at 8:00 am ET (13:00 GMT / 14:00 CET). “The third quarter was marked by robust license revenues and high gross margins, due to the approval of three new biosimilars across key global markets. We also held a leading market position with our Humira biosimilar in the U.S. and Stelara biosimilar in Europe,” said Robert Wessman, Chairman and CEO of Alvotech. “Resolving issues identified during the FDA inspection of our Reykjavik facility in July is a top priority. As we announced earlier, we have revised our full year outlook, to $570-$600 m...